An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in 
ovarian cancer cells

Sheng, Qing; Liu, Xinggang; Fleming, Eleanor; Yuan, Karen; Chen, Jinyun; Moustafa, Zeinab; Thomas, Roman K.; Greulich, Heidi; Schinzel, Anna C.; Zaghlul, Sara; Batt, David; Ettenberg, Seth; Meyerson, Matthew; Schoeberl, Birgit; Kung, Andrew L.; Hahn, William C.; Drapkin, Ronny; Livingston, David M.; Liu, Joyce

doi:10.1016/j.ccr.2009.12.047

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

MPS-Authors

Sheng, Qing
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Liu, Xinggang
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Fleming, Eleanor
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Yuan, Karen
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Chen, Jinyun
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Moustafa, Zeinab
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

/persons/resource/persons147315

Thomas, Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Greulich, Heidi
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Schinzel, Anna C.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Zaghlul, Sara
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Batt, David
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Ettenberg, Seth
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Meyerson, Matthew
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Schoeberl, Birgit
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Kung, Andrew L.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Hahn, William C.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Drapkin, Ronny
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Livingston, David M.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Liu, Joyce
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Sheng, Q., Liu, X., Fleming, E., Yuan, K., Chen, J., Moustafa, Z., et al. (2010). An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell, 17(10), 298-310. doi:10.1016/j.ccr.2009.12.047.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-D22F-D